JP2012525362A5 - - Google Patents

Download PDF

Info

Publication number
JP2012525362A5
JP2012525362A5 JP2012507808A JP2012507808A JP2012525362A5 JP 2012525362 A5 JP2012525362 A5 JP 2012525362A5 JP 2012507808 A JP2012507808 A JP 2012507808A JP 2012507808 A JP2012507808 A JP 2012507808A JP 2012525362 A5 JP2012525362 A5 JP 2012525362A5
Authority
JP
Japan
Prior art keywords
cis
product according
pharmaceutical product
trans
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012507808A
Other languages
English (en)
Japanese (ja)
Other versions
JP5608220B2 (ja
JP2012525362A (ja
Filing date
Publication date
Priority claimed from GBGB0907601.9A external-priority patent/GB0907601D0/en
Application filed filed Critical
Publication of JP2012525362A publication Critical patent/JP2012525362A/ja
Publication of JP2012525362A5 publication Critical patent/JP2012525362A5/ja
Application granted granted Critical
Publication of JP5608220B2 publication Critical patent/JP5608220B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012507808A 2009-05-01 2010-04-22 神経損傷の治療を目的としたpufaの使用 Expired - Fee Related JP5608220B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0907601.9A GB0907601D0 (en) 2009-05-01 2009-05-01 Novel methods
GB0907601.9 2009-05-01
PCT/GB2010/000817 WO2010125330A1 (en) 2009-05-01 2010-04-22 Use of pufas to treat nerve damage

Publications (3)

Publication Number Publication Date
JP2012525362A JP2012525362A (ja) 2012-10-22
JP2012525362A5 true JP2012525362A5 (cg-RX-API-DMAC10.html) 2013-12-26
JP5608220B2 JP5608220B2 (ja) 2014-10-15

Family

ID=40792178

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012507808A Expired - Fee Related JP5608220B2 (ja) 2009-05-01 2010-04-22 神経損傷の治療を目的としたpufaの使用

Country Status (14)

Country Link
US (1) US20120122982A1 (cg-RX-API-DMAC10.html)
EP (1) EP2424519A1 (cg-RX-API-DMAC10.html)
JP (1) JP5608220B2 (cg-RX-API-DMAC10.html)
KR (1) KR101664518B1 (cg-RX-API-DMAC10.html)
CN (1) CN102448453B (cg-RX-API-DMAC10.html)
AU (1) AU2010243368C1 (cg-RX-API-DMAC10.html)
BR (1) BRPI1009922A2 (cg-RX-API-DMAC10.html)
CA (1) CA2762009C (cg-RX-API-DMAC10.html)
GB (1) GB0907601D0 (cg-RX-API-DMAC10.html)
MX (1) MX2011011615A (cg-RX-API-DMAC10.html)
NZ (1) NZ596674A (cg-RX-API-DMAC10.html)
SG (1) SG175848A1 (cg-RX-API-DMAC10.html)
WO (1) WO2010125330A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201108571B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
ES2727387T3 (es) * 2013-11-15 2019-10-15 Ds Biopharma Ltd Sal de lisina de ácido 15-hidroxi-8(Z),11(Z),13(E)-eicosatrienoico
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3261684D1 (en) * 1981-05-12 1985-02-07 Ici Plc Pyrrole derivatives
US4532254A (en) * 1983-03-17 1985-07-30 Kaken Pharmaceutical Co., Ltd. Inhibitor of aldose reductase
AU599515B2 (en) * 1987-09-16 1990-07-19 Taiho Pharmaceutical Co., Ltd. Thienopyrimidine derivatives
EP2140863A1 (en) * 1993-06-09 2010-01-06 Martek Biosciences Corporation Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of neurological disorders
US7015249B1 (en) * 1997-12-12 2006-03-21 Purdue Research Foundation Methods and compositions for treating diabetes
US6107349A (en) * 1998-04-16 2000-08-22 Mantynen; Philip R. Method and composition for treating psoriasis
GB9827391D0 (en) * 1998-12-11 1999-02-03 Fundation O N C F Aldose reductase inhibitors and pharmaceutical compositions
CA2304906A1 (en) * 2000-04-07 2001-10-07 1411198 Ontario Limited 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
PL357678A1 (en) * 2000-04-28 2004-07-26 Sankyo Company, Limited Ppargamma modulators
ES2240657T3 (es) * 2001-02-28 2005-10-16 Pfizer Products Inc. Compuestos de sulfonilpiridazinona utiles como inhibidores de aldosa reductasa.
AU2002304931A1 (en) * 2001-06-08 2002-12-23 University Of British Columbia Methods for treating disorders of the nervous and reproductive systems
ES2536710T3 (es) * 2002-03-25 2015-05-27 Arimed Inc. Nuevo uso terapéutico de LPC, ligandos agonistas específicos para el receptor G2A
WO2006137435A1 (ja) * 2005-06-22 2006-12-28 National University Corporation Gunma University Gタンパク質共役型受容体g2aの作動薬、及びg2a活性調節薬のスクリーニング方法
EP2179999A4 (en) * 2007-12-18 2011-06-08 Univ Toyama Nat Univ Corp CONDENSED TRICYCLIC COMPOUND WITH ALDOSIS REDUCTASE HARMFUL EFFECT

Similar Documents

Publication Publication Date Title
RU2014131014A (ru) Димерные соединения-агонисты рецептора fgf (fgfr), способ их получения и их терапевтическое применение
RU2016137678A (ru) Соединения с эфирными группами для лечения опосредованных комплементом нарушений
RU2013155586A (ru) [1,3]оксазины
AR063872A1 (es) Derivados de acetileno como inhibidores de estearoil coa desaturasa
RU2016103139A (ru) Новые композиции для предупреждения и/или лечения лизосомных болезней накопления
JP2018502101A5 (cg-RX-API-DMAC10.html)
RU2008107733A (ru) Ингибиторы gsk-3
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
AU2014367781B2 (en) Therapeutic and/or preventive agent comprising 1-indansulfamide derivative for pain
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
RU2013130878A (ru) Гидроксилированные производные аминотриазола в качестве агонистов рецептора alx
RU2016125313A (ru) Способы лечения ишемического и геморрагического инсульта, повреждения спинного мозга, повреждения черепного нерва, повреждения периферического нерва и нейродегенеративных расстройств или когнитивных нарушений
JP2015502371A5 (cg-RX-API-DMAC10.html)
RU2008141907A (ru) Конъюгированные липидные производные
RU2009128968A (ru) Производные изосорбидмононитрата для лечения повышенной внутриглазной гипертензии
JP5959083B2 (ja) (1R−trans)−N−[[2−(2,3−ジヒドロ−4−ベンゾフラニル)シクロプロピル]メチル]プロパンアミドの代謝物
AU2013253409A1 (en) Analgesic
KR20160005356A (ko) 방사선완화 약제학적 제형
RU2013107659A (ru) ИНГИБИТОР КАЗЕИНКИНАЗЫ 1δ И КАЗЕИНКИНАЗЫ 1ε
CA2762009C (en) Use of pufas to treat nerve damage
KR102332035B1 (ko) 정상적인 노화 과정의 반전 및 수명 연장 방법
JP2014510022A5 (cg-RX-API-DMAC10.html)
RU2018130994A (ru) Новое соединение бисфосфоновой кислоты
JP2021535210A5 (cg-RX-API-DMAC10.html)
RU2009130726A (ru) Терапия